European medicinal cannabis company PHCANN International has signed an exclusive distribution agreement with Canngea in Australia and New Zealand.
Under the arrangement, licensed B2B manufacturer and wholesale distributor Canngea will register, import, store and distribute PHCANN products in both markets.
CEO Zlatko Keskovski said Canngea won the distribution rights after an exhaustive competitive process.
“PHCANN’s philosophy has always been to keep the patient at the heart of what we do, and Canngea’s focus on science and compliance is very much in line with our own values,” he said.
Canngea has a partnership with the University of Sydney to facilitate research and development.
Keskovski added: “We have been observing the Australian and New Zealand markets for some time and feel they have matured to work in line with healthcare professionals and meet patient expectations of quality and consistency.”
Canngea managing director Ryan Ballantyne said: “PHCANN International has responded to market demand for high-quality medical cannabis by investing in new facilities, including a fully equipped cannabinoid research and testing laboratory to research the microbiology and stability data of cannabinoids in all forms.”
“This level of quality is exactly what Australian and New Zealand customers deserve and are demanding, and via this agreement, PHCANN and Canngea are uniquely placed to meet that demand.”